These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29993249)

  • 41. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
    Sakkiah S; Ng HW; Tong W; Hong H
    Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Specific interactions between androgen receptor and its ligand: ab initio molecular orbital calculations in water.
    Kobayashi I; Takeda R; Suzuki R; Shimamura K; Ishimura H; Kadoya R; Kawai K; Takimoto-Kamimura M; Kurita N
    J Mol Graph Model; 2017 Aug; 75():383-389. PubMed ID: 28641211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In silico and in vitro assessment of androgen receptor antagonists.
    Serçinoğlu O; Bereketoglu C; Olsson PE; Pradhan A
    Comput Biol Chem; 2021 Jun; 92():107490. PubMed ID: 33932781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity.
    Thompson J; Saatcioglu F; Jänne OA; Palvimo JJ
    Mol Endocrinol; 2001 Jun; 15(6):923-35. PubMed ID: 11376111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
    Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
    Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer.
    Southwell J; Chowdhury SF; Gottlieb B; Beitel LK; Lumbroso R; Purisima EO; Trifiro M
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):138-46. PubMed ID: 18619542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.
    Helsen C; Dubois V; Verfaillie A; Young J; Trekels M; Vancraenenbroeck R; De Maeyer M; Claessens F
    Mol Cell Biol; 2012 Aug; 32(15):3033-43. PubMed ID: 22645304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions.
    Kaczmarczyk SJ; Green JE
    Nucleic Acids Res; 2003 Aug; 31(15):e86. PubMed ID: 12888538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
    Doamekpor SK; Peng P; Xu R; Ma L; Tong Y; Tong L
    Acta Crystallogr F Struct Biol Commun; 2023 Apr; 79(Pt 4):95-104. PubMed ID: 36995121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
    Fu W; Zhang M; Liao J; Tang Q; Lei Y; Gong Z; Shan L; Duan M; Chai X; Pang J; Tang C; Wang X; Xu X; Li D; Sheng R; Hou T
    J Med Chem; 2021 Dec; 64(23):17221-17238. PubMed ID: 34809430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.
    Jasuja R; Ulloor J; Yengo CM; Choong K; Istomin AY; Livesay DR; Jacobs DJ; Swerdloff RS; Miksovská J; Larsen RW; Bhasin S
    Mol Endocrinol; 2009 Aug; 23(8):1231-41. PubMed ID: 19443608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists.
    Wang Y; Han R; Zhang H; Liu H; Li J; Liu H; Gramatica P
    Biomed Res Int; 2017; 2017():3572394. PubMed ID: 28293633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer.
    Singh AN; Baruah MM; Sharma N
    Sci Rep; 2017 May; 7(1):1955. PubMed ID: 28512306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of the binding modes of the first- and second-generation antiandrogens with respect to F876L mutation.
    Shao G; Bao J; Pan X; He X; Qi Y; Zhang JZH
    Chem Biol Drug Des; 2021 Jul; 98(1):60-72. PubMed ID: 33905591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.
    Bohl CE; Miller DD; Chen J; Bell CE; Dalton JT
    J Biol Chem; 2005 Nov; 280(45):37747-54. PubMed ID: 16129672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity.
    Tamura H; Yoshioka M; Hasegawa M; Hosoda A; Matsugi M; Akamatsu M
    Bioorg Med Chem; 2013 Jun; 21(11):2968-74. PubMed ID: 23611768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stepwise androgen receptor dimerization.
    van Royen ME; van Cappellen WA; de Vos C; Houtsmuller AB; Trapman J
    J Cell Sci; 2012 Apr; 125(Pt 8):1970-9. PubMed ID: 22328501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions.
    Ghadessy FJ; Lim J; Abdullah AA; Panet-Raymond V; Choo CK; Lumbroso R; Tut TG; Gottlieb B; Pinsky L; Trifiro MA; Yong EL
    J Clin Invest; 1999 Jun; 103(11):1517-25. PubMed ID: 10359561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.
    Meyer R; Wolf SS; Obendorf M
    J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):1-14. PubMed ID: 17587566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.